Prostate cancer is one of the most common malignancies in men. It is highly treatable in early stages; however, once the cancer becomes metastatic, it is extremely difficult to cure. Yoshioka and colleagues demonstrated that a significant fraction of advanced, hormone refractory prostate cancers express high levels of the protein beta-4 integrin. Using a mouse model of prostate cancer, they found that loss of the beta-4 integrin gene significantly inhibited prostate tumor growth and progression. The image above is an MRI of a wild type mouse (left) and a beta-4 integrin-deficient mouse (right) with the prostate tumor outlined in red.
The contextual signals that regulate the expansion of prostate tumor progenitor cells are poorly defined. We found that a significant fraction of advanced human prostate cancers and castration-resistant metastases express high levels of the β4 integrin, which binds to laminin-5. Targeted deletion of the signaling domain of β4 inhibited prostate tumor growth and progression in response to loss of p53 and Rb function in a mouse model of prostate cancer (PB-
Toshiaki Yoshioka, Javier Otero, Yu Chen, Young-Mi Kim, Jason A. Koutcher, Jaya Satagopan, Victor Reuter, Brett Carver, Elisa de Stanchina, Katsuhiko Enomoto, Norman M. Greenberg, Peter T. Scardino, Howard I. Scher, Charles L. Sawyers, Filippo G. Giancotti